Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Valeri, Antonio ^a   Alonso Ferrero, Maria Eugenia ^a   Río, Paula ^a   Pujol, María Roser ^a,b   Casado, José A ^a   Pérez, Laura ^a   Jacome, Ariana ^a   Agirre, Xabier ^c   Calasanz, Maria José ^c   Hanenberg, Helmut ^d,e   Surrallés, Jordi ^a,b   Prosper, Felipe ^c   Albella, Beatriz ^a   Bueren, Juan A ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d Department of Pediatric Oncology   (Germany)

^e RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BRCA1 PROTEIN; CD34 ANTIGEN; FANCONI ANEMIA GROUP D2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETROVIRUS VECTOR; CROSS LINKING REAGENT; FANCD2 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CENTROSOME; CHROMOSOMAL INSTABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; GENETIC STABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UBIQUITINATION; BIOSYNTHESIS; CHROMOSOME; CHROMOSOME ABERRATION; FANCONI ANEMIA; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; METHODOLOGY; RETROVIRUS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ULTRASTRUCTURE;

ANTIGENS, CD34; CELL LINE, TUMOR; CENTROSOME; CHROMOSOME ABERRATIONS; CHROMOSOMES; CROSS-LINKING REAGENTS; DNA DAMAGE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FUSION PROTEINS, BCR-ABL; GENES, BRCA1; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROSCOPY, FLUORESCENCE; RETROVIRIDAE;

EID: 78650802580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015525     Document Type: Article

References (53)

1. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, et al. (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277-280.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, et al. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99.
3. LugoTG, Pendergast AM,Muller AJ,WitteON(1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082.
4. Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630.
5. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
6. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441-453.
7. Burke BA, Carroll M (2010) BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia Epub ahead of print.
8. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, et al. (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275: 24273-24278.
9. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, et al. (2004) BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104: 3746-3753.
10. Dierov J, Sanchez PV, Burke BA, Padilla-Nash H, Putt ME, et al. (2009) BCR/ ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 23: 279-286.
11. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, et al. (2006) BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108: 319-327.
12. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T (2008) BCR/ ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 22: 1969-1972.
13. Deutsch E, Dugray A, Abdul Karim B, Marangoni E, Maggiorella L, et al. (2001) BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97: 2084-2090.
14. Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls homologydirected DNA repair. Mol Cell 4: 511-518.
15. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet M-L, et al. (2003) Downregulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101: 4583-4588.
16. Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, et al. (2008) BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 68: 6884-6888.
17. Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, et al. (2009) BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 114: 1813-1819.
18. Moldovan GL, D'Andrea AD (2009) How the Fanconi Anemia Pathway Guards the Genome. Annu Rev Genet 43: 223-249.
19. Levitus M, Joenje H, de Winter JP (2006) The Fanconi anemia pathway of genomic maintenance. Cell Oncol 28: 3-29.
20. Cohn MA, D'Andrea AD (2008) Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol Cell 32: 306-312.
21. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
22. Jose-Eneriz ES, Roman-Gomez J, Cordeu L, Ballestar E, Garate L, et al. (2008) BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol 142: 571-582.
23. Jacome A, Navarro S, Casado JA, Rio P, Madero L, et al. (2006) A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. Hum Gene Ther 17: 245-250.
24. Casado JA, Callen E, Jacome A, Rio P, Castella M, et al. (2007) A comprehensive strategy for the subtyping of Fanconi Anemia patients: conclusions from the Spanish Fanconi Anemia research network. J Med Genet 44: 241-249.
25. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, et al. (2002) S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100: 2414-2420.
26. Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, et al. (1995) Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 85: 2233-2237.
27. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, et al. (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7: 249-262.
28. Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, et al. (2003) BRCA1- independent ubiquitination of FANCD2. Mol Cell 12: 247-254.
29. Bogliolo M, Lyakhovich A, Callen E, Castella M, Cappelli E, et al. (2007) Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. Embo J 26: 1340-1351.
30. Altiok S, Batt D, Altiok N, Papautsky A, Downward J, et al. (1999) Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/ AKT in breast cancer cells. J Biol Chem 274: 32274-32278.
31. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, et al. (2004) BRCA1- dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 24: 8457-8466.
32. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, et al. (2005) Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 19: 1192-1197.
33. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, et al. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187.
34. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, et al. (1995) BCR-ABLmediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86: 1148-1158.
35. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and - independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 20: 1179-1186.
36. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, et al. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9: 568-574.
37. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, et al. (2004) Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 64: 2994-2997.
38. Tischkowitz MD, Morgan NV, Grimwade D, Eddy C, Ball S, et al. (2004) Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18: 420-425.
39. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, et al. (2004) Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165: 651-657.
40. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, et al. (2008) Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 30: 299-306.
41. Lyakhovich A, Surralles J (2006) Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett 232: 99-106.
42. Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, et al. (2002) Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood 99: 3197-3204.
43. Zhao RC, Jiang Y, Verfaillie CM (2001) A model of human p210(bcr/ABL)- mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 97: 2406-2412.
44. Koptyra M, Stoklosa T, Hoser G, Seferynska L, Glodkowska E, et al. (2008) Monoubiquitination of the Fanconi Anemia D2 (FANCD2) Protein Regulates the Transforming Potential of BCR/ABL. Blood (ASH Annual Meeting Abstracts) 112: 112.
45. Xu X, Weaver Z, Linke SP, Li C, Gotay J, et al. (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3: 389-395.
46. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC (1991) Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11: 1107-1113.
47. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, et al. (2008) AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 68: 9404-9412.
48. Tonic I, Yu WN, Park Y, Chen CC, Hay N (2010) Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem 285: 23790-23798.
49. Fukasawa K (2005) Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19.
50. Auerbach AD, Wolman SR (1976) Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 261: 494-496.
51. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG (1998) BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16: 335-348.
52. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R (2003) Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A 100: 6523-6528.
53. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, et al. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311.